Previous 10 | Next 10 |
BOSTON and DURHAM, N.C., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Parexel, a leading global clinical research organization (CRO), today announced the promotions of Peyton Howell to the newly-created role of Chief Operating and Growth Officer and Amy McKee, MD, to Chief Medical Officer and Global ...
Commercial-stage biotech BioCryst Pharmaceuticals, Inc. ( NASDAQ: BCRX ) announced Wednesday that the FDA granted the orphan drug designation for its experimental drug BCX9250 for the treatment of the rare genetic disorder fibrodysplasia ossificans progressiva (FOP). With ...
RESEARCH TRIANGLE PARK, N.C., Aug. 31, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for BCX9250 for the treatment of fibrodysplasia ossificans progressiva (FOP)...
The U.S. Department of Health and Human Services (HHS) exercised an option to buy an additional 10K doses of BioCryst Pharmaceuticals' ( NASDAQ: BCRX ) antiviral influenza therapy Rapivab for ~$7M. Rapivab (peramivir injection) purchase by the HHS Admini...
RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the U.S. Department of Health and Human Services (HHS) has exercised its option to purchase an additional 10,000 doses of BioCryst’s antiviral influe...
The Saudi Food and Drug Authority (SFDA) approved BioCryst Pharmaceuticals' ( NASDAQ: BCRX ) oral medicine Orladeyo (berotralstat) to prevent attacks of hereditary angioedema (HAE) in patients 12 years and older. In September 2021, BioCryst signed a distribution a...
RESEARCH TRIANGLE PARK, N.C., Aug. 18, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Saudi Food and Drug Authority (SFDA) has approved oral, once-daily ORLADEYO ® (berotralstat) to prevent attacks of hereditary angioedema (...
Image source: The Motley Fool. BioCryst Pharmaceuticals (NASDAQ: BCRX) Q2 2022 Earnings Call Aug 04, 2022 , 8:30 a.m. ET Operator Continue reading For further details see: BioCryst Pharmaceuticals (BCRX) Q2 2022 Earnings Call Transcript ...
BioCryst Pharmaceuticals, Inc. (BCRX) Q2 2022 Earnings Conference Call August 04, 2022 08:30 AM ET Company Participants John Bluth - SVP, IR and Corporate Communications Jon Stonehouse - CEO Anthony Doyle - CFO Dr. Bill Sheridan - CMO Charlie Gayer - CCO ...
Shares of the rare disease specialist BioCryst Pharmaceuticals (NASDAQ: BCRX) were up by a noteworthy 20% on heavy volume at 9:38 a.m. ET Thursday morning. Although the biotech reported encouraging 2022 second-quarter results prior to today's opening bell, the real needle mover ...
News, Short Squeeze, Breakout and More Instantly...
BioCryst Pharmaceuticals Inc. Company Name:
BCRX Stock Symbol:
NASDAQ Market:
BioCryst Pharmaceuticals Inc. Website:
RESEARCH TRIANGLE PARK, N.C., July 09, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the General Directorate of Medicines, Supplies and Drugs (DIGEMID) in Peru has granted approval for oral, once-daily ORLADEYO ® (berotralstat) for t...
2024-06-27 04:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-07 10:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...